Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

ESCRT-0 regulates AMPA receptor currents and Ca<sup>2+</sup>- dependent signaling.

bioRxiv : the preprint server for biology·2026

Same author

Social anxiety is associated with greater autonomic and visuocortical generalization of conditioned aversive responses to faces.

Cognitive, affective & behavioral neuroscience·2026

Same author

Resolving competition in auditory cortex: effects of emotional content and misophonia sensitivity.

Cerebral cortex (New York, N.Y. : 1991)·2026

Same author

Prognostic utility of circulating tumor DNA in classical hodgkin lymphoma: A systematic review and individual participant data bayesian meta-analysis.

Critical reviews in oncology/hematology·2026

Same author

Tissue block-resolved developmental transcriptomic atlas of human fetal brainstem reveals gene modules with implications for neurological disorders.

Frontiers in cell and developmental biology·2025

Same author

Bayesian multilevel modeling of group and participant level effect sizes: Stronger inter-individual differences in pupil dilation compared to EEG alpha power during aversive conditioning.

bioRxiv : the preprint server for biology·2025

Search research articles

Related Experiment Video

Updated: Sep 21, 2025

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

Plasma p-tau181 associated with structural changes in mild cognitive impairment.

Fardin Nabizadeh^1,2, Mohammad Balabandian³, Mohammad Reza Rostami³

¹Neuroscience Research Group (NRG), Universal Scientific Education and Research Network (USERN), Tehran, Iran. fardinnabizade1378@gmail.com.

Aging Clinical and Experimental Research

|June 1, 2022

Summary

Plasma levels of hyperphosphorylated tau 181 (p-tau181) correlate with brain structure changes in mild cognitive impairment (MCI). This finding supports p-tau181 as an early biomarker for Alzheimer's disease (AD) neurodegeneration.

Keywords:

Atrophy Blood biomarker Mild cognitive impairment p-tau181

More Related Videos

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on ¹⁸F-AV-1451

Published on: April 18, 2025

A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid

A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid

Published on: September 3, 2021

Related Experiment Videos

Last Updated: Sep 21, 2025

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on ¹⁸F-AV-1451

Published on: April 18, 2025

A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid

A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid

Published on: September 3, 2021

Area of Science:

Neuroscience
Biomarker Discovery
Neuroimaging

Background:

Alzheimer's disease (AD) is a progressive neurodegenerative disorder causing dementia.
Brain changes like gray matter atrophy and white matter damage precede clinical symptoms by ~15 years.
Identifying early biomarkers is crucial for AD diagnosis and prognosis.

Purpose of the Study:

To investigate the association between plasma and cerebrospinal fluid (CSF) p-tau181 levels and structural brain changes in MCI patients.
To evaluate plasma p-tau181 as a potential diagnostic marker for early AD-related neurodegeneration.

Main Methods:

Cross-sectional study of 461 MCI patients from the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort.
Analysis of CSF and plasma p-tau181 levels.
Voxel-wise partial correlation analyses examining relationships with cortical thickness, volume, surface area, and subcortical volume.

Main Results:

Significant negative correlations were found between elevated plasma p-tau181, CSF total tau, and CSF p-tau181 levels with widespread structural brain changes.
These correlations indicate a link between tau biomarkers and neurodegeneration in MCI.

Conclusions:

Plasma p-tau181 levels are associated with structural brain alterations in individuals with MCI.
Plasma p-tau181 shows promise as a biomarker for detecting early-stage AD and neurodegeneration.